cyrilzakka/clinical-trials huggingface dataset:
The Physical Activity Post Myocardial Infarction SWEDEHEART Prospective Cohort Study

The association between objectively measured physical activity intensities (light, moderate and vigorous), sedentary time and clinical outcomes has not been clarified in patients after a myocardial infarction.

The overall objective of the study is to explore associations between accelerometer measured physical activity and clinical outcomes after a myocardial infarction. Moreover, the association between changes in physical activity and outcomes will be assessed.

It is estimated to include 4000 patients with myocardial infarction during 2 years. Patients will wear the accelerometer for 7 days at follow-up visits (2 months and 1 year) after discharge. The investigators will examine the dose-response relations of several exposure variables from the accelerometer measurements with the outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent
* Diagnosis of a type 1 myocardial infarction registered in SWEDEHEART
* Age 18-79 years at discharge from hospital
* Attending the first visit in the cardiac rehabilitation (CR) registry SEPHIA (2 months after discharge)

Exclusion Criteria:

* Inability to understand Swedish
* Non-ambulatory
* Any mental condition that may interfere with the possibility for the patient to comply with the study protocol
Acute Myocardial Infarction in Cancer Patients

Using national health insurance service database, current study aim to evaluate the risk and prognosis of acute myocardial infarction in cancer patients and to find the optimal treatment strategy for acute myocardial infarction that can improve long-term prognosis.

This study will be conducted using Korean National Health Insurance Service database. Patients who were diagnosed with cancer from 2002 to 2021 will be included in the study. Using the selected patients, current study will analyze the incidence and prognosis of acute myocardial infarction in cancer patients and the prognosis according to the treatment method for acute myocardial infarction will be compared. Primary outcome will be all-cause death. Secondary outcomes will be myocardial infarction, revascularization, hospitalization for heart failure, stroke, and clinically relevant bleeding.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with cancer between 2002 and 2021
* Patients who were diagnosed with acute myocardial infarction after cancer diagnosis

Exclusion Criteria:

* Patients who died during period of cancer diagnosis
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD

This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content, cardiometabolic risk factors and gut microbiota among both men and women with MASLD.


Eligibility Criteria:
Main Inclusion Criteria:

* Men and women aged between 18 and 75 years (including ranges);
* CAP Score ≥288dB/m with liver stiffness results \<8kPa (corresponding to F0 to F1 fibrosis score) assessed by Fibroscan®;
* BMI ≥25 and \<40 kg/m2 and WC thresholds according to the NAFLD Nomenclature consensus group (Rinella. 2023. Hepatology);
* Weight stable within ± 5% in the last three months.

Main Exclusion Criteria:

* Contraindications to MRI, Fibroscan® and DEXA;
* Suffering from a metabolic disorder susceptible to significantly affect glucose metabolism or plasma lipid levels or that might affect the study outcomes according to the investigator;
* Suffering from an uncontrolled arterial hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg);
* With a history of atherosclerotic cardiovascular disease (ASCVD);
* Taking medication which may affect the study outcomes;
* Alcohol consumption over ≥10 drinks/week for women and ≥15 drinks/week for men (women consuming more than 3 drinks/day and men consuming more than 4 drinks/day will also be excluded) or not agreeing to keep their alcohol consumption habits unchanged throughout the study.
CC100: Safety and Tolerability of Single Doses

The purpose of this study is to see if CC100, given by mouth, is safe and is tolerated in increasing doses. How long the drug remains in the body will also be calculated.

Approximately 18 healthy subjects will be randomized to receive by mouth either 3 single increasing doses of CC100 or 1 dose of placebo and 2 increasing doses of CC100. Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose. Subjects are required to stay in the Clinic for approximately 24 hours following each dose. Subjects may choose to have an optional lumbar puncture following the 3rd dose of study drug.

Eligibility Criteria:
Inclusion Criteria:

* Men must practice a reliable method of birth control during study and for 2 weeks following study. Women must be non-fertile or post-menopausal.

Exclusion Criteria:

* Have serious or unstable illnesses as determined by the investigator.
* Have current or a history of asthma, or severe drug allergies or pollen allergy.
* Have used medications (except for calcium supplements or externally applied eye drops or antibiotics) within 30 days prior to dosing or are expected to use other medications during the study.
* Have had serious infectious disease affecting the brain within the preceding 5 years; or have known or existing evidence of serious infection.
* Have laboratory test values that are considered clinically significant as determined by the investigator.
* Have ECG abnormalities that are clinically significant.
* Have donated blood (a pint or more) or received an experimental drug within 30 days prior to dosing.
* Have a history of chronic alcohol or drug abuse within the past 2 years.
Thyroid Function in Late Preterm Infants

Transient hypothyroxinemia (TH) is a condition characterized by low levels of serum thyroxine (T4) and normal levels of thyroid stimulating hormone (TSH). TH in premature infants has been found to be related to severity of illness. T4 levels in very low birth weight infants born prematurely has been found to be inversely correlated to severity of illness. In very low birth weight infants, TH has been associated with poor outcomes. Little is known about thyroid function in late preterm infants.

Hypotheses:

1. Ill late preterm infants will have lower total T4 levels than healthy late preterm infants.
2. Total T4 and possibly TSH levels will be inversely correlated with short-term outcomes.
3. Late Preterm infants born by cesarean section will have lower T4 levels compared to those born by vaginal birth.


Eligibility Criteria:
Inclusion Criteria:

* any infant born between 34 0/7 weeks and 36 6/7 weeks gestation born at Christiana Hospital

Exclusion Criteria:

* outborn infants
* infants with major congenital anomalies
Efficacy and Safety of Green Tea Polyphenol in De Novo Parkinson's Disease Patients

The purpose of this study is to determine whether Green Tea Polyphenol, an extraction from Green Tea is effective and safe in the treatment of De Novo Parkinson's disease Patients without taking any antiparkinsonism drug

The primary outcome measurement is UPDRS using a delay start design. Total 480 de novo PD patients divided into three dosage groups of green tea polyphenol and one placebo control group. Patients will be treated for one year.

Eligibility Criteria:
Inclusion Criteria:

* Willing and able to give informed consent
* Age 30 years or older at time of diagnosis of Parkinson's disease
* Diagnosed as having typical PD
* Parkinson's disease duration of no more than 5 years
* No current dopaminergic or other forms of anti-parkinsonism therapy
* Hoehn and Yahr stage \< 3
Living Donor Uterus Transplantation Between Identical Twins

Living donor uterus transplantation between identical twins, with IVF before and ET several months after transplantation. The donor should have completed childbirth.

Living donor uterus transplantation between identical twins, with IVF before and ET several months after transplantation. The donor should have completed childbirth.

Eligibility Criteria:
Inclusion Criteria:

* age below 40 years
* absolute uterine factor infertility
* BMI\<30-

Exclusion Criteria:

* systemic disease
Role of an E-cigarette on Smoking Displacement in Smokers With Schizophrenia

It is well established in the scientific literature that people with schizophrenia smoke tobacco cigarettes at rates up to three times that of the general population, relapse more frequently, and die an average of 25 years earlier from cigarette smoking and other life-style attributable illnesses. Electronic cigarettes (e-cigarettes) are becoming increasingly popular with smokers worldwide and new research suggests that e-cigarettes are appealing to smokers with schizophrenia. There is a paucity of research focused on the experience of smokers with schizophrenia who decide to try an e-cigarette. A well-designed prospective-observational study is needed to learn more about the influence of e-cigarette use on cigarette smoking behavior and mental and physical health among smokers with schizophrenia. In response, the investigators have designed a study titled, Role of an electronic cigarette on smoking displacement in smokers with schizophrenia: A prospective 3-month pilot study (SchizEcig).

This is a prospective 3 month pilot study to observe cigarette use behavior among people with a schizophrenia spectrum disorder diagnosis who smoke conventional tobacco cigarettes, do not intend to reduce or quit smoking, and are invited to use an e-cigarette. The investigators are interested to know if e-cigarette use is associated with cigarette smoking displacement. Displacement is defined as switching from conventional tobacco cigarettes to e-cigarettes. The investigators will also monitor for physical and mental health, including blood pressure, weight, and scores from the Scale for the Assessment of Negative Symptoms (SANS) and the Scale for the Assessment of Positive Symptoms (SAPS) as well as any reported adverse events participants' feel are attributed to e-cigarette use and participants' perceptions of the sensory experience associated with e-cigarette use.

Eligibility Criteria:
Inclusion Criteria:

Clinical diagnosis of a schizophrenia spectrum disorder

Non-hospitalized persons

Regular smokers who report smoking 20 or more cigarettes per day who have smoked at least 100 cigarettes in their lifetime, and are not intending to reduce or quit

Has agreed to try an e-cigarette

Must be able to provide written informed consent

Must be able to read, write and communicate in English proficiently

Must have access to a computer with internet

Must have the ability to work a computer and navigate the internet easily

Exclusion Criteria:

Non-smokers Persons without a schizophrenia spectrum disorder diagnosis

Hospitalized persons

Cardio vascular disease

Respiratory disease

Use of smokeless tobacco or any other tobacco products besides cigarettes.

Use of nicotine replacement therapy or other smoking cessation pharmaco-therapies within the last 3 months

Pregnancy or breastfeeding
Comparison of Electroacupuncture and Thread Embedded Acupuncture With Dietary Intervention in Obese Patients

The purpose of this study is to compare the effectiveness between electroacupuncture treatment with dietary intervention and thread embedded acupuncture with dietary intervention in reducing body weight, waist circumference, and leptin level in obese patients.

The purpose of this study is to describe reducement in body weight, waist circumference, and leptin level in obese patients with dietary intervention and electroacupuncture or dietary intervention with thread embedded acupuncture. It is also to analyze mean differences of body weight, waist circumference, and leptin level in obese patients between the two interventions. The results of the study expected to be used as an operating standard procedure for obese patients.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 - 60 years
* Obese with Body Mass Index (BMI) 25 - 35 kg/m\^2
* Waist circumference male \> 90 cm and female \> 80 cm
* Willing to participate in the study by signing an informed consent
* Willing to follow the study process until it is finished

Exclusion Criteria:

* Pregnancy
* Post partum \< 6 months
* Diabetes (Blood glucose POCT (Point of Care Testing) \>= 200 mg/dl)
* Hypertension (Blood pressure \>= 140/90 mmHg)
* Fever \> 38\^C
* Has a history of contraindication for electroacupuncture such as history of heart diseases, pace maker, arrhythmia
* Has a history of contraindication for thread embedded acupuncture such as allergy of PDO (Polydioxanone), blood clotting disorder, consumption of anticoagulant drugs, local infection or wound on embedded site
* Has a history of weight loss drugs consumption (such as orlistat, phentermine, diethylpropion) or slimming supplements (green tea, jati belanda/Guazuma ulmifolia) for the last 25 hours.
* History of liver disease, kidney disease
* Has had acupuncture therapy for obesity in the last six months
Early Use of Prone Position in ECMO for Severe ARDS

Venovenous extracorporeal membrane oxygenation (VV-ECMO) is widely used in the salvage treatment of critical acute respiratory distress syndrome (ARDS). However, reducing lung injury, accelerating lung recovery, shortening VV-ECMO support time, and decreasing complications during the treatment need further study. By changing the body position of ARDS patients, the prone position can increase the lung's dorsal ventilation and improve the lung's ventilation/blood flow ratio to improve oxygenation. Previous multicenter studies have proved that the prone position can significantly reduce the mortality of patients with moderate and severe ARDS. However, patients with severe ARDS rescue by VV-ECMO rarely combine with a prone position.On the one hand, with the support of ECMO, the patient's oxygenation will be significantly improved, and they will no longer need the assistance of a prone position. In addition, the ECMO cannula brings some challenges to implementing a prone position. Only a few cohort studies have reported that VV-ECMO combined with a prone position could improve the oxygenation index and respiratory system compliance during the late treatment period.

The initial reason for PP in ARDS patients was to alleviate severe hypoxemia, as it was an efficient means to improve oxygenation in most patients. However, some patients were categorized as non-responders in the PP regarding oxygenation, which caused VV-ECMO therapy to be initiated. Should we decide to perform PP after VV-ECMO therapy no longer? This study evaluates whether early use of PP during VV-ECMO would increase the proportion of patients successfully weaned from VV-ECMO support compared with supine positioning in severe ARDS patients who received PP before ECMO.


Eligibility Criteria:
Inclusion Criteria:

1. met the diagnostic criteria of Berlin's definition for ARDS;
2. had undergone prone positing before VV-ECMO；
3. receiving VV-ECMO support

Exclusion Criteria:

1. spinal instability；
2. elevated intracranial pressure;
3. facial/neck trauma;
4. recent sternotomy;
5. large ventral surface burn;
6. multiple trauma with unstabilized fractures;
7. severe hemodynamic instability;
8. massive hemoptysis;
9. high risk of requiring CPR or defibrillation;
A Pilot Study Testing Onabotulinum Toxin a Versus Incobotulinum Toxin a Injections for Facial Wrinkles

The purpose of this study is to compare the effectiveness of Botox® (Onabotulinum Toxin A) versus Xeomin® (incobotulinum toxin A) for the treatment of forehead and glabellar (vertical lines between the eyebrows) wrinkles.

Subjects will be screened, photographed, assessed, and randomized to be injected with onabotulinum toxin A on one side and incobotulinum toxin A on the other side during their first clinic visit. Subjects will return for a 2 week, 2 month, 3 month, 4 month, 5 month, and 6 month follow-up to have photographs taken by the unblinded research assistant at relaxed and full contraction.

This study is a pilot study designed to determine feasibility of these procedures.

Eligibility Criteria:
Inclusion Criteria:

1. Females and males
2. In good health
3. Is 20-65 years of age
4. Has static and moderate dynamic forehead/glabellar wrinkles
5. Has willingness and the ability to understand and provide informed consent and communicate with the study staff

Exclusion Criteria:

1. Pregnant or lactating
2. Younger than 20 or older than 65 years of age
3. Has received the following treatments in the forehead or glabellar region:

   1. botulinum toxin injections in the past 6 months
   2. ablative laser procedure in the past 6 months
   3. radiofrequency device treatment in the past 6 months
   4. ultrasound device treatment in the past 6 months
   5. medium to deep chemical peel in the past 6 months
   6. temporary soft tissue augmentation material in the area to be treated in the past year
   7. semi-permanent soft tissue augmentation material in the area to be treated in the past 2 years
   8. permanent soft tissue augmentation material in the area to be treated
4. Is planning to receive within the next 6 months, any cosmetic procedure (such as any chemical peels, botulinum toxin injections, ablative or non-ablative laser procedures, filler injections, radiofrequency procedures, dermabrasion, ultrasound and face lifting procedures) in the forehead or glabellar region.
5. Is planning to use tretinoin or retinoic acid in the next 6 months
6. Has an active infection in the forehead or glabellar region (excluding mild acne)
7. Is allergic to cow's milk protein
8. Is allergic to albumin
9. Taking aminoglycoside
10. Is currently using anticoagulation therapy
11. Has a history of bleeding disorders
12. Has a mental illness
13. Unable to understand the protocol or to give informed consent
Cumulative Live Birth Rate (CLBR) After a Complete IVF Cycle: a Single Center Retrospective Study

We need to identify a new parameter to evaluate the success rate of IVF techniques. CLBR has been suggested as a suitable way for reporting success of IVF program: it implies capturing the totality of live birth episodes following successive treatments. For patients CLBR is easy to understand because it summarizes the chance of a live birth over an entire treatment period. CLBR per oocyte retrieval is more meaningful as it is the best indicator of quality and success in IVF and it allows the best indicator of quality and success in IVF with different strategies for freezing embryos.

Traditionally, studies about In Vitro Fertilization (IVF) examine and report the 'per cycle' and 'per embryo transfer procedure' probability of pregnancy and delivery .Thus, each IVF cycle is considered as a unique entity even if several embryo transfers (ET) have been performed after a single ovarian stimulation.

Thanks to the latest technological refinements, in recent years the number of thawed frozen ETs has greatly increased and has become an essential feature of IVF procedures .This practice has been encouraged by the strategy of preferring single ET for reducing multiple pregnancy and preventing ovarian hyperstimulation in high risk women.

Moreover, at first infertility counseling patients usually want to know which is their possibility to have a live birth child with ART treatment, after the first stimulation cycle, also involving the chances after frozen ET or frozen oocytes injection.

Live birth rate (LBR) after a single fresh or frozen ET appears, at present time, to be an insufficient parameter for a realistic evaluation of the efficacy of an IVF program.

We need to identify a new parameter for the evaluation of the success rate of IVF techniques which should incorporate outcomes associated with a single controlled ovarian stimulation cycle. Specifically, Cumulative live birth rate (CLBR) has been suggested as a suitable way for reporting success of IVF program : it implies capturing the totality of live birth episodes following successive treatments.

For patients CLBR is very reliable and easy to understand because it summarizes the chance of a live birth over an entire treatment period . CLBR per oocyte retrieval is more meaningful as it is the best indicator of quality and success in IVF and it allows the best indicator of quality and success in IVF with different strategies for freezing embryos.

The aim of the present study was to report our experience on CLBR after the first stimulation cycle and to determinate which prognostic factors contribute to positive pregnancy outcomes.

Eligibility Criteria:
Inclusion Criteria:

* All patients admitted to Humanitas Research hospital for undergoing their first IVF cycle

Exclusion Criteria:

* cycle with any pre-implatation genetic test
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.

This is a Phase 2 study designed to evaluate the efficacy and safety of ABT-126 in approximately 410 adults with mild to moderate Alzheimer's disease. Subjects will be randomized to one of 5 treatment groups (ABT-126, donepezil or placebo) for a 24-week treatment period.

Eligibility Criteria:
Inclusion Criteria:

* The subject and caregiver must voluntarily sign and date an informed consent. If the subject does not have the capacity to provide informed consent, full informed consent must be obtained from the subject's representative and assent must be obtained from the subject.
* The subject is a male or female between the ages of 55 and 90 years, inclusive, at Screening Visit 1.
* The subject meets the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable Alzheimer's disease.
* The subject has a Mini-Mental Status Examination (MMSE) total score of 10 to 24, inclusive, at Screening Visit 1.
* The subject has a Cornell Scale for Depression in Dementia (CSDD) score ≤ 10 at Screening Visit 1.
* The subject has a Modified Hachinski Ischemic Scale (MHIS) score of ≤ 4 at Screening Visit 1.
* With the exception of a diagnosis of mild to moderate AD and the presence of stable medical conditions, the subject is in general good health, based upon the results of medical history, physical examination, vital signs, laboratory profile, and a 12-lead electrocardiogram (ECG).
* The subject has an identified, reliable caregiver who will provide support and ensure compliance with the study medication and procedures, and provide accurate information about the subject's status during the study.

Exclusion Criteria:

* The subject is currently taking or has taken a medication for the treatment of Alzheimer's disease or dementia within 60 days prior to Screening Visit 1, or is participating in cognitive therapy for the treatment of Alzheimer's disease or dementia.
* The subject has clinically significant abnormal laboratory values at Screening Visit 1 as determined by the investigator.
* The subject has a history of any significant neurologic disease other than Alzheimer's disease including Parkinson's disease, multi-infarct or vascular dementia, Huntington's disease, normal pressure hydrocephalus, progressive supranuclear palsy, multiple sclerosis, any seizures, mental retardation or a history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities.
* In the opinion of the investigator, the subject has any clinically significant uncontrolled medical or psychiatric illness.
* The subject has a known hypersensitivity or intolerance to donepezil that lead to discontinuation or a known reported history of donepezil treatment failure.